TEVA - Teva Pharma CEO Dismisses Split Speculations Expects Significant Interest For Its API Business Divestiture: Report | Benzinga
As previously speculated, Teva Pharmaceutical Industries (NYSE:TEVA) will not undergo a split into two separate entities.
On Tuesday, Teva’s Chief Executive, Richard Francis, said the company would continue as a unified entity, managing the generics business and its branded drugs.
However, the company will stay unified, and “from an infrastructure point of view, (the two businesses) complement each other incredibly well,” Reuters highlighted, citing the CEO at a news briefing.
Also Read: Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise.
The generics side of Teva plays a crucial role in funding the ...